Genitourinary Cancers | Specialty

Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell Carcinoma

October 19th 2015

Brian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses a phase Il study that examined axitinib as a second-line therapy for metastatic renal cell carcinoma.

Renal Cell Carcinoma Vaccine Fails to Improve Outcomes

October 15th 2015

The IMA901 multipeptide vaccine added to sunitinib failed to improve outcomes versus sunitinib alone as first-line therapy for advanced/metastatic renal cell carcinoma.

Ten Years After Sorafenib, TKIs Are Still Advancing Kidney Cancer Treatment

October 13th 2015

Robert Figlin, MD, discusses the evolution of TKIs in renal cell carcinoma, the novel agents and changes to established therapies he is most excited about, and the challenges that still remain.

In Kidney Cancer, Better Outcomes Demonstrated With Nephron-sparing Surgery

October 12th 2015

Patients with renal cell carcinoma have better outcomes when undergoing nephron-sparing surgery rather than radical nephrectomy.

Are Surgery and Chemotherapy Sufficient to Treat Locally Advanced Bladder Cancer?

October 11th 2015

The challenge of pelvic failure following contemporary cystectomy has been engaged and the clinical trials to pursue the amelioration of this problem have commenced.

PD-L1 Inhibitor Avelumab May Improve Survival in Metastatic Urothelial Carcinoma

October 7th 2015

Andrea B. Apolo, MD, explains the challenges that still remain regarding toxicity and future combination therapies with avelumab, and the potential of checkpoint inhibition in urothelial carcinoma going forward.

Dr. Andrea Apolo on Treatment Challenges in Metastatic Bladder Cancer

October 2nd 2015

Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses treatment challenges for patients with refractory, metastatic urothelial carcinoma.

FDA Schedules Advisory Meeting for MCNA in Bladder Cancer

October 2nd 2015

The FDA has scheduled an advisory hearing to discuss the biologics license application for the immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-Guérin therapy.

Dr. Andrea Apolo on Avelumab in Metastatic Bladder Cancer

September 28th 2015

Andrea B. Apolo, MD, medical oncologist at the National Cancer Institute, chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses a phase 1b trial investigating avelumab, an anti-PD-L1 antibody, in patients with refractory, metastatic urothelial carcinomas.

Atezolizumab Provides Viable Treatment Option in Metastatic Urothelial Carcinoma

September 27th 2015

Second-line atezolizumab demonstrated significant clinical benefit in patients with metastatic urothelial carcinoma who had a poor prognosis after progressing following platinum-based chemotherapy.

Dr. Toni Choueiri on Cabozantinib Versus Everolimus in Renal Cell Carcinoma

September 27th 2015

Toni Choueiri, MD, Clinical Director, Lank Center for Genitourinary Oncology Director, Kidney Cancer Center, Senior Physician at Dana-Farber Cancer Institute, discusses the results of the METEOR trial in advanced renal cell carcinoma (RCC).

FDA Approves TAS-102, New Nivolumab Breakthrough Designation, Two Priority Reviews, and More

September 25th 2015

Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

September 25th 2015

Nivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.

Second-Line Cabozantinib Improves PFS in Advanced RCC

September 25th 2015

Second-line treatment with cabozantinib reduced the risk of progression or death by 42% compared with everolimus in patients with advanced renal cell carcinoma.

PD-1 and PD-L1 May Be Actionable Targets in Sarcomatoid Renal Cell Carcinoma

September 21st 2015

Renal cell carcinoma with sarcomatoid differentiation, a histology that is often resistant to targeted therapies and interleukin-2 immunotherapy (IL-2), may respond to anti–PD-1/PD-L1 therapies.

Axitinib Dose Titration Improves Outcomes in Metastatic Renal Cell Carcinoma

September 16th 2015

Titrating dose levels of axitinib (Inlyta) improved response rates and extended overall survival by 12.3 months in patients with metastatic renal cell carcinoma.

FDA Grants Nivolumab Breakthrough Designation in Renal Cell Carcinoma

September 16th 2015

Nivolumab (Opdivo) has received an FDA breakthrough therapy designation for the treatment of patients with advanced renal cell carcinoma.

Dr. Larkin on Lenvatinib Plus Everolimus in Patients With RCC

September 15th 2015

James Larkin, MD, PhD, medical oncologist, Royal Marsden Hospital, discusses a phase II study that examined the combination of lenvatinib and everolimus versus either agent alone in patients with renal cell carcinoma.

FDA Grants Intravesical Immunotherapy Priority Review for Bladder Cancer

August 28th 2015

The FDA has assigned a priority review designation to the intravesical immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-Guerin therapy.

Cabozantinib Granted FDA Breakthrough Designation in Renal Cell Carcinoma

August 24th 2015

Cabozantinib (Cometriq) has received a breakthrough therapy designation from the FDA for the treatment of patients with advanced renal cell carcinoma following one prior therapy.